Market Place
Sourcing Support
Neurimmune to regain rights to brain amyloid depleter for Alzheimer™s disease
31 Jan 2024 //
GLOBENEWSWIRE
Neurimmune to preset results of phase 1b proof-of-concept study of NI006
19 May 2023 //
PHARMABIZ
Biogen CEO points to risk in neuroscience as 3 programs cut
21 Jul 2022 //
FIERCEBIOTECH
AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug
01 Mar 2022 //
REUTERS
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
17 Jan 2022 //
PRNEWSWIRE
FDA Approval of Aducanumab
07 Jun 2021 //
PRNEWSWIRE
Neurimmune Announces the Initiation of a Phase 1 Study of NI006
27 Feb 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.